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Highlights 
 Genome-editing is revolutionising all aspects of cellular biology, including 
pharmacological studies, including the ability to define ‘on-target’ effects of 
pharmaceutical ligands.  
 The ability to eliminate expression from single or multiple genes provides ‘knock-out’ 
rather than ‘knock-down’ cell lines derived from widely used model cell systems, as 
well as the capacity to explore the specific functions of closely related proteins. 
 Such approaches have provided new insights into the biological roles of a number of 
poorly characterised GPCRs. 
 Elimination of expression of entire subfamilies of G protein  subunits and of both 
the widely expressed arrestin proteins has provided new understanding of the roles of 
G protein-mediated versus arrestin-mediated signalling from GPCRs. 
 Genome-editing will be expanded rapidly to target other cell signalling pathway 
components. 
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Abstract 20 
Rapid developments in genome-editing, based largely on CRISPR/Cas9 technologies, are 21 
offering unprecedented opportunities to eliminate the expression of single or multiple gene 22 
products in intact organisms and in model cell systems. Eliminating individual G protein-23 
coupled receptors, both single and multiple G protein subunits, and arrestin adaptor proteins 24 
is providing new, and sometimes unanticipated, insights into molecular details of regulation 25 
of cell signalling pathways and the behaviour of receptor ligands. Genome-editing is certain 26 
to become a central component of therapeutic target validation and will provide 27 
pharmacologists with new understandings of the complexities of action of novel and 28 
previously studied ligands as well as the transmission of signals from individual cell surface 29 
receptors to intracellular signalling cascades. 30 
 31 
Challenges in pharmacological research 32 
Defining both target selectivity and ‘on-target’-mediated effects of tool compounds and 33 
drug-like synthetic ligands have long been major challenges for pharmacologists. Moreover, 34 
unravelling the relative contributions of multiple intracellular signalling pathways and 35 
cascades initiated by activation of a single type of cell-surface receptor to a downstream 36 
cellular end-point or a physiological effect has also been highly reliant on the availability, 37 
effectiveness, and selectivity of various inhibitors and antagonists (see Glossary). In the 38 
absence of such tool compounds, and prior to the recent development of genome-editing 39 
approaches, particularly those based on the CRISPR/Cas9 system (Text Box 1), such 40 
analyses had often been limited to the use of ‘antisense’ and other mRNA ‘knock-down’ 41 
strategies. Using these it was anticipated that observed reduction in levels of a mRNA would 42 
be followed rapidly by substantial reduction in cellular levels and function of the 43 
corresponding protein(s). Whilst this may generally be true for proteins that turnover rapidly 44 
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it is not the case for proteins with longer cellular half-life. Knock-down strategies have 45 
produced a vast array of semi-quantitative studies that have linked the extent of assessed 46 
‘knock-down’ (at both mRNA and protein level) with reduction in function. Gene ‘knock-47 
outs’ in both mice and non-mammalian model organisms have provided cells (e.g. mouse 48 
embryo fibroblasts) and tissues to explore the implications of true elimination of expression 49 
of proteins of interest. However, maintained lack of expression in intact organisms can 50 
frequently lead to substantial alterations in other cellular proteins that attempt to compensate 51 
and maintain homeostatic balance. Although this has been improved by moves from ‘whole 52 
body’ knock-out to more tissue-specific and conditional elimination of expression, many of 53 
the same issues remain. As discussed by Alvarez-Curto et al., [1] knock-out of expression of 54 
various genes may be better tolerated, without inducing alterations in levels of other network 55 
components, in simple model cell systems maintained in cell culture as many of these are 56 
transformed and genetically modified in their base-state (Text Box 2).     57 
In this article we focus on the use of CRISPR/Cas9-based genome-editing in such model 58 
cell systems and on the lessons learned to date from such studies about signal selection and 59 
signal transduction pathways promoted by members of the G protein-coupled receptor 60 
(GPCR) superfamily. Many of these studies have been performed using human embryonic 61 
kidney (HEK)293 cells (Figure 1) and their various derivatives. This is useful because 62 
HEK293 cells are widely used by the research community to study underpinning mechanisms 63 
of cellular signalling. However, a range of other cell lines and primary cell types have also 64 
been used, and this is likely to expand rapidly as genome-editing approaches become ever 65 
more widely adopted.  In the studies we will consider various G protein subunits, arrestins or 66 
other signalling pathway components have been eliminated. In a number of cases expression 67 
of GPCRs has also been targeted. This is already providing novel insights into roles of poorly 68 
characterised GPCRs. Furthermore, this approach is likely to have increasing utility in 69 
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providing null backgrounds for ligand screening programmes where in the cell background 70 
of choice various GPCRs are expressed at sufficiently high level to generate signals that can 71 
obfuscate efforts to define novel ligands for so called orphan GPCRs or complicate analysis 72 
of effects at closely-related members of the GPCR superfamily.  73 
 74 
Elimination of expression of GPCRs 75 
mRNAs encoding a substantial number of individual GPCRs are expressed at detectable 76 
levels in virtually all tissues and cell types [2, 3, 4]. Even for widely used model cell systems, 77 
including HEK293 cells, that are often considered as a ‘blank canvas’ for introduction and 78 
analysis of receptors of interest, studies have shown detectable expression of a wide range of 79 
GPCR family members [5]. Unsurprisingly, pluripotent embryonic stem cells display high 80 
level expression of various members of the Frizzled subfamily of GPCRs as these play key 81 
roles in embryonic development [6]. Moreover, subsets of the members of the 82 
lysophospholipid (lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) activated) 83 
receptor family are widely expressed, and co-expressed. For example, three distinct S1P 84 
receptors and a further LPA receptor are expressed endogenously by CHO-K1 cells [7]. This 85 
is a model cell line widely used in ligand screening projects. This pattern of co-expression 86 
reflects the importance of these receptors in cellular growth control. This does mean, 87 
however, that cells lacking expression of genuine LPA- and S1P-activated GPCRs are 88 
uncommon. This has likely contributed to still unsubstantiated suggestions that LPA or 89 
highly related molecules are the endogenously generated agonists for a number of other 90 
poorly characterised GPCRs [8, 9] beyond the currently accepted six LPA receptors (LPA1-6) 91 
and five S1P receptors (S1P1-5).  92 
The key signalling mechanisms of many GPCRs are well established. However, even for 93 
the 2-adrenoceptor for which a very well described and extensive pharmacopeia is available, 94 
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researchers have recently employed CRISPR/Cas9-based genome-editing to define 95 
unambiguously the contribution of this receptor to a less well established signalling outcome. 96 
Galaz-Montoya et al. [10] eliminated endogenous expression of the 2-adrenoceptor from 97 
HEK293 cells to ensure that -adrenoceptor agonist function in these cells that resulted in 98 
elevation of intracellular Ca2+ levels truly reflected activation of this receptor. This was 99 
despite concurrent pharmacological studies providing all but unequivocal evidence that this 100 
must be the case. This level of analysis indicates that CRISPR/Cas9-based genome-editing is 101 
becoming available to many and is convenient to use, as long as simple and robust strategies 102 
are in place to confirm successful elimination of expression in genome-edited cell clones 103 
(Text Box 2). Galaz-Montoya et al. [10] then performed further pharmacological studies that 104 
appeared to rule out a role of the adenylyl cyclase stimulatory G protein Gs in generating the 105 
Ca2+ signal. Related studies by Stallaert et al., [11] also explored mechanisms underlying the 106 
ability of 2-adrenoceptor agonists to increase intracellular Ca2+ levels in HEK293 cells. In 107 
part, these studies also used genome-edited cells, but in this case engineered to lack 108 
expression of the  subunit of Gs. Now 2-adrenoceptor agonists were unable to generate the 109 
Ca2+ signal, suggesting a direct role for Gs. Further studies demonstrated that the 110 
mechanism reflected 2-adrenoceptor-mediated release of ATP. This nucleotide then acted as 111 
an autocrine factor to activate an endogenously expressed P2Y purinoceptor which, via its 112 
own Gq/G11-based coupling to phospholipase C, induced the Ca
2+ elevation [11]. This 113 
highlights an example in which incomplete appreciation of the endogenous expression 114 
patterns of GPCRs can generate results and lead to conclusions that on first sight may appear 115 
unexpected or incongruous.  116 
At the other extreme in terms of the current level of understanding of the roles of a 117 
GPCR, a genome-wide screen was conducted in the human myeloid leukemia cell line KBM7 118 
to identify expressed proteins required for the cellular action of the Pseudomonas aeruginosa 119 
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produced exotoxin A. One of the identified proteins was the orphan GPCR GPR107 [12] 120 
about which virtually nothing was known. Subsequent CRISPR/Cas9-based elimination of 121 
GPR107 from HeLa cells substantially reduced the ability of exotoxin A to kill these cells. 122 
Further studies showed GPR107 to be localised to the trans-Golgi network and to play a role 123 
in intracellular vesicle trafficking [12]. In a similar vein, Bostaille et al., [13] employed 124 
CRISPR/Cas9-mediated elimination of the poorly understood adhesion family GPCR Adgra2 125 
(also designated GPR124) from HEK293 cells to allow detailed study of trafficking of 126 
variants of this receptor in an Adgra2-‘null’ cell background. Potential roles of GPRC5A, 127 
another ‘orphan’ GPCR, but part of the class C or glutamate-like receptor subfamily, have 128 
also been studied following CPISPR/Cas9-mediated gene targeting in a number of cell lines 129 
[14]. These studies indicated an important role for GPRC5A in cell adhesion, and linked this 130 
GPCR to the function of integrins via activation of the RhoA and Rac1 small GTPases. 131 
Regulation of these pathways has also been posited to suggest a role for GPRC5A in cancer 132 
progression [14]. Also in a therapeutic context, although the outcomes were predictable 133 
because it is well established to act as a co-receptor that allows infection by strains of the 134 
human immunodeficiency virus type 1, CPISPR/Cas9-mediated elimination of the chemokine 135 
receptor CXCR4 from cells, including human primary CD4+ T cells, was shown to result in 136 
resistance to viral entry [15]. 137 
 138 
Elimination of expression of subunits of heterotrimeric G proteins 139 
Although many GPCRs are often presented as interacting predominantly with a single G 140 
protein, or with members of only one of the four subfamilies of heterotrimeric G proteins 141 
(Figure 1), this is frequently an over-simplification. Indeed, at least in transfected cell 142 
systems, many GPCRs can interact with multiple G protein subclasses, although there may be 143 
a rank-order or hierarchy to this. A substantial number of studies have been published in the 144 
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last two years that have used HEK293 cell lines isolated following genome-editing designed 145 
to eliminate expression of various sets of G protein  subunits.  146 
 147 
Elimination of Gq/G11 148 
The first published of these studies employed a clone of HEK293 cells that had been 149 
genome-edited to eliminate expression of both Gq and G11. These two G proteins are 150 
closely related, are generally co-expressed, and are the principal means to link cell surface 151 
GPCRs to activation of phospholipase C1. This results in the generation of inositol 1,4,5 152 
trisphosphate and elevation of cytosolic Ca2+ levels via release from the endoplasmic 153 
reticulum. The two other members of the human Gq family, G14 and G16, are not 154 
expressed by HEK293 cells [5] (Figure 1). In recent years, a number of chemical inhibitors 155 
of members of the Gq/G11 family G proteins have become available [16-17] (Text Box 3). 156 
As part of a far-reaching study that defined that the depsipeptide FR900359 was a potent and 157 
selective inhibitor of G proteins of this sub-family Schrage et al., [18] showed that whilst 158 
ATP-mediated activation of an endogenously expressed P2Y purinoceptor is observed in 159 
parental HEK293 cells, this was lacking in the Gq/G11-null genome-edited cells. The effect 160 
of ATP was restored by re-introduction of Gq into the genome-edited cells and in both 161 
parental HEK293 cells and Gq re-transfected Gq/G11-null cells the Ca2+ signal induced by 162 
ATP was fully blocked by addition of FR900359 [18]. A key component of this study was 163 
that re-introduction into the Gq/G11-null cells of one of the proteins eliminated by the 164 
genome-editing process was both able and sufficient to fully restore function and phenotype 165 
[18]. This confirms that the deficit observed in the genome-edited cell line was directly due to 166 
the lack of this protein. Similar re-capitulation of function or phenotype studies should be an 167 
integral part of the experimental design of any project that eliminates expression of a protein 168 
of interest. Not least, this reflects that genome editing can result in ‘off-target’ effects that 169 
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result in the elimination of expression of gene products other than those the approach was 170 
designed to modify (Text Box 4). Equivalent results to those with ATP were also obtained 171 
when using the acetylcholine mimetic carbachol to activate the muscarinic M3 receptor [18], 172 
another GPCR that is endogenously expressed to significant levels by HEK293 cells. 173 
Interestingly, lack of expression of Gq and G11 did not affect cell viability or proliferation 174 
[18]. However, compared to parental HEK293 cells migration towards foetal bovine serum of 175 
the cells lacking both Gq and G11 is markedly impaired [19]. Re-introduction of Gq into 176 
the Gq/G11-knock out cells enhanced the migration response to transforming growth factor- 177 
(TGF-), while both cell lines showed a similar signalling response (SMAD phosphorylation) 178 
to TGF-, thus indicating that Gq and/or G11 is important for integrating migratory signals 179 
[19].  180 
Subsequently these cells have been used in a number of other studies. Alvarez-Curto 181 
et al. [1] transfected such Gq/G11-null cells and isolated clones stably expressing either 182 
wild type mouse free fatty acid receptor 4 (mFFA4) or a form of this receptor in which C-183 
terminal amino acids that become phosphorylated in response to agonist activation in the wild 184 
type were altered from Ser/Thr to Ala [20]. The wild type receptor was activated in both 185 
parental and Gq/G11-deficient cells as defined by agonist-induced phosphorylation of 186 
residues Thr347 and Ser350 within the receptor C-terminal tail.  However, agonism could not 187 
generate elevated levels of either inositol phosphates or Ca2+ in the Gq/G11-deficient cells 188 
[1]. More interestingly, although many GPCRs, including mFFA4, are able to enhance 189 
phosphorylation and activation of the ERK1/2 MAP kinases when expressed in parental 190 
HEK293 cells, this was completely lacking in the cells genome-edited to lack expression of 191 
Gq and G11 [1]. There is substantial debate as to the contribution of G protein- and non-192 
canonical, potentially arrestin-mediated, signalling to this end-point following activation of 193 
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GPCRs. However, these results imply that, at least for mFFA4, signals that regulate ERK1/2 194 
phosphorylation are dependent entirely on these G proteins. In support of this, in parental 195 
HEK293 cells mFFA4-mediated ERK1/2 MAP kinase phosphorylation was completely 196 
eliminated in the presence of an earlier described Gq/G11 inhibitor YM-254890 [21] (Text 197 
Box 3) that is closely related to FR900359. Further studies employing HEK293 cells genome-198 
edited to lack expression of a broader range of G protein  subunits (Gαs, Gαolf, Gαq, Gα11, 199 
Gα12 and Gα13) have essentially confirmed, at least in this cell type, an absence of detectable 200 
GPCR-mediated arrestin signalling in the absence of receptor interaction with G protein  201 
subunits [22].  The Gq plus G11 genome-edited cells have also been used to provide 202 
information to support the idea that a modified form of a muscarinic M3 receptor, designed to 203 
retain the ability to signal via Gq but to lose interactions with arrestin adaptor proteins, does 204 
indeed retain competence to activate this G protein [23]. Moreover, within a larger study 205 
designed to understand the interactions of the hallucinogen lysergic acid diethylamide (LSD) 206 
with the serotonin 5-HT2B receptor Wacker et al. [24] expressed this receptor in both parental 207 
and Gq/G11-null HEK293 cells to illustrate a minimal role for these G proteins on the rate 208 
of dissociation of LSD from the receptor. Although focussed largely on the molecular basis 209 
for why human GPRC6A is predominantly retained intracellularly when used in expression 210 
studies, Jørgensen et al. [25] also used the Gq/G11-null genome-edited HEK293 cells to 211 
allow introduction of a previously characterised receptor-promiscuous mutant of Gαq 212 
(Gly66AspGαq) [26] to define the relative signalling effectiveness of variants and mutants of 213 
GPRC6A. 214 
 215 
Elimination of Gs/Golf  216 
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The family of adenylyl cyclase stimulatory G proteins contains splice variants of Gs that are 217 
expressed ubiquitously, as well as the highly related G protein Golf (olfactory) (Figure 1). 218 
Initially considered to be limited to the nasal neuroepithelium, Golf is now appreciated to 219 
have a wider expression pattern, particularly in regions of the brain. As noted earlier, Stallaert 220 
et al. [11] generated Gαs/Gαolf-deficient HEK293 cells and demonstrated that β2-221 
adrenoceptor-induced Ca2+ response was mediated by Gs family proteins. 222 
As part of an extensive study into mechanisms linking the 2-adrenoceptor to 223 
phosphorylation of ERK1/2 MAP kinases O’Hayre et al. [27] used HEK293 cells genome-224 
edited to lack expression of both Gs and Golf. Lack of these G proteins all but eliminated 225 
the ability of the 2-adrenoceptor agonist isoproterenol to induce ERK1/2 MAP kinase 226 
phosphorylation. Importantly, this was restored by re-introduction of Gs into the cells [27]. 227 
As for FFA4 [1], expression of a form of the 2-adrenoceptor that lacked key sites of agonist-228 
induced phosphorylation, and that therefore interacts poorly with arrestins, resulted in greater 229 
levels of  ERK1/2 phosphorylation in parental cells than was generated by the wild type 2-230 
adrenoceptor [27]. In concert with [1] and [22] these studies indicate that for distinct, well 231 
characterised GPCRs, even though they interact predominantly with different G protein 232 
classes, regulation of the ERK1/2 MAP kinases is largely, if not exclusively, G protein-233 
dependent. Further studies that consider this question in cells lacking expression of arrestins 234 
will be reviewed later. HEK293 cells lacking Gs/Golf have also been used within a broader 235 
set of studies designed to assess the contribution of Gs-regulation of p70 S6 kinase activity 236 
within a pre-assembled β-arrestin/p70 S6 kinase/ribosomal protein S6 complex that enhances 237 
mRNA translation [28]. 238 
In efforts to assess conformational changes in activated G proteins and how this might 239 
correlate with agonist efficacy, Furness et al. [29] stably expressed the calcitonin receptor in 240 
these Gs/Golf-null HEK293 cells. They then introduced transiently sets of Gs G protein 241 
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FRET-sensor pairings to focus on these, without receptor interactions also occurring with 242 
endogenously expressed Gs. By expressing such FRET sensors in the Gs/Golf-null cells 243 
these studies showed the FRET sensors mediate cAMP response to various ligands in a 244 
manner similar to native Gs. When membranes from such cells were challenged with different 245 
agonists of the calcitonin receptor clear, if subtle, differences were noted in the organisation 246 
of the G protein complex when using either human or salmon calcitonin as agonist [29].  247 
The GNAS gene that encodes Gs can also generate a longer, N-terminally extended, 248 
variant described as XLαs. It was recently indicated that XLαs can interact with various 249 
intracellular sorting proteins that are key contributors to clathrin-mediated endocytosis, 250 
including nexin-9 and dynamins [30]. Elimination of XLαs from the osteocyte-like cell line 251 
Ocy454 using CRISPR/Cas9 increased internalisation of transferrin, whilst further studies 252 
indicated this to be a specific role for XLαs rather than for conventional Gs [30]. 253 
 254 
Elimination of G12/G13, or G12/G13 and Gq/G11 255 
As discussed earlier, key roles of Gq and/ or G11 are broadly understood. However, 256 
despite studies on knock-out mouse lines and the production and use of mouse embryo 257 
fibroblast cells derived from such animals, the roles of G12 and /or G13 are generally poorly 258 
understood [31, 32]. In significant part this reflects that activation of these G proteins does 259 
not directly regulate second messenger levels or other easy-to-measure and high-throughput 260 
endpoints. HEK293 cells express both G12 and G13 [5] (Figure 1) and genome-editing has 261 
been used to generate clones of HEK293 cells lacking both G12 and G13 [33, 34] and even 262 
lines lacking each of Gq, G11, G12, and G13 [22, 34, 35, 36]. 263 
Ligand screening strategies for novel activators of GPCRs have often centred to trying to 264 
develop assays that can be utilised broadly, no matter the G protein-coupling preference and 265 
profile of the receptor. Approaches to this have included transfection alongside a receptor of 266 
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interest of the ‘universal’ G protein G16 [37] and the co-transfection of a cocktail of 267 
chimeric G protein  subunits [38]. Recently a transforming growth factor  (TGF) 268 
shedding assay was introduced [39] and shown to be able to report activation of a broad 269 
range of heterologously expressed GPCRs. Sergeev et al. [34] demonstrated, by using free 270 
fatty acid receptor 2 (FFA2), that the TGF shedding assay is suitable if the receptor couples 271 
effectively to any combination of Gq, G11, G12, and/or G13. This conclusion was based 272 
on the lack of agonist-induced shedding of TGF when FFA2 was introduced into HEK293 273 
cells that had been genome-edited to eliminate all four of these G protein subunits, and the 274 
restoration of such activity with re-introduction of any one of these four G proteins into the 275 
genome-edited cells [34] (Figure 2). As FFA2 is also able to activate various pertussis toxin-276 
sensitive Gi-family G proteins [40, 41] and a number of these are also expressed 277 
endogenously by HEK293 cells [5] (Figure 1), these studies also illustrated that activation of 278 
members of this G protein group is not able to induce TGFshedding. The FFA2 allosteric 279 
agonist AZ1729, although able to produce a conformation of the receptor able to engage with 280 
Gi-family G proteins, is not able to do so for Gq/G11 G proteins [41].  The extreme Gi-281 
directed ‘bias’ of this ligand was now also shown to extend to a lack of capacity to activate 282 
G12 and/or G13 via FFA2 [34].  By contrast orthosteric agonists, including the short chain 283 
fatty acids that are the endogenous agonists for this receptor, allowed engagement with all of 284 
these G proteins subtypes [34]. Devost et al. [36] used these same quadruple G protein  285 
subunit-deleted cells to show loss of coupling of various GPCRs known to engage with these 286 
G proteins to stimulate a serum response factor-based gene reporter construct.  Once again, 287 
individual re-introduction of each of Gq, G11, G12, or G13 restored responsiveness to 288 
intramolecular BRET-based biosensors of the angiotensin AT1 receptor and in a manner 289 
dependent on the specific construction of the sensor [36]. 290 
 291 
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Elimination of arrestins 292 
 Four members of the arrestin family play key roles in desensitisation of responses of 293 
GPCRs following initial agonist-induced receptor activation [42]. Although arrestin-1 and 294 
arrestin-4 have very limited expression profiles, both arrestin-2 and arrestin-3 (also still 295 
widely designated -arrestin-1 and -arrestin-2 respectively) are expressed ubiquitously, 296 
including by HEK293 cells [5] (Figure 1). When bound to an agonist-activated GPCR 297 
arrestins block access of G proteins to the receptor.  In recent years much broader roles of 298 
arrestins have been uncovered in which they may initiate signal transduction events distinct 299 
from, and apparently not dependent upon, G protein activation [42, 43, 44]. Understanding 300 
the contributions and roles of arrestin-2 and arrestin-3 as initiators of signal transduction via 301 
distinct pathways is at the heart of the push to identify ‘bias’ ligands that may lead to the 302 
development of improved therapeutics [41, 42, 43]. Indeed, results from mouse knock-out 303 
models clearly implicate arrestins in roles beyond, and distinct from, their capacity to limit 304 
and desensitise G protein-mediated signalling [44, 45]. Although often assumed to be 305 
functionally redundant, arrestin-2 and arrestin-3 clearly fulfil distinct roles [45]. Genome 306 
editing has been used to eliminate the expression of both arrestin-2 and arrestin-3 in HEK293 307 
cells [1, 27], and such arrestin-null cells have been central to a number of recent studies. As 308 
highlighted earlier, alongside cells genome-edited to lack both Gq and G11, [1] expressed 309 
both wild type and phosphorylation-deficient mouse FFA4 in HEK293 cells genome-edited 310 
to lack both arrestin-2 and arrestin-3. Although wild type FFA4 internalises extensively and 311 
rapidly from the surface of parental HEK293 cells upon addition of an agonist [46], 312 
occupation of either form of this receptor now failed to cause substantial internalisation in the 313 
arrestin-2 plus arrestin-3 null cells [1]. FFA4 agonist-mediated phosphorylation of the 314 
ERK1/2 MAP kinases was also preserved in the absence of arrestins [1]. Moreover, in both 315 
wild type and arrestin-null HEK293 cells much greater elevation of ERK1/2 MAP kinase 316 
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phosphorylation was produced by the phosphorylation-deficient mFFA4 receptor. This 317 
indicates that this effect cannot simply reflect lack of arrestin-mediated desensitisation of the 318 
receptor but must be linked intrinsically to its phosphorylation state [1]. As well as using the 319 
same arrestin2/3-null HEK293 cells [27] recently additionally employed selective small 320 
interfering RNA knockdown of each of arrestin-2 and arrestin-3 to indicate a key role for 321 
specifically arrestin-3 in agonist-induced internalisation of the 2-adrenoceptor. These 322 
workers then extended this to studies that used TALEN (transcription activator–like effector 323 
nuclease)-induced elimination of arrestin-2. Once again 2-adrenoceptor-mediated ERK1/2 324 
phosphorylation was enhanced, rather than decreased, in the complete absence of arrestins 325 
[27]. By contrast, the ERK1/2 phosphorylation response was completely silenced in 326 
Gs/Golf-null cells [27] as mentioned previously. It is important to note, however, that 327 
whilst [47] also noted enhanced ERK1/2 phosphorylation in arrestin2/3-null HEK293 cells 328 
upon agonist activation of the A variant of the chemokine CXCR3 receptor, they rather 329 
reported reduced activity via the B variant of this receptor.  This suggests that there may be 330 
substantial variation in mechanisms of regulation of ERK1/2 phosphorylation by different 331 
GPCRs when expressed in the same cell background. The HEK293 cells genome-edited to 332 
lack expression of both arrestin-2 and arrestin-3 have also been used to complement other 333 
approaches.  In studies of mutated variants of arrestin-3 that appeared to interact 334 
spontaneously with the M2 muscarinic acetylcholine receptor it was concluded that Lys
139Ile-335 
arrestin-3 was indeed able to interact with this receptor in an agonist-independent fashion 336 
[48]. In a similar vein, [49] used HEK293 cells lacking both arrestin-2 and arrestin-3, but also 337 
engineered additionally to lack expression of the endogenously expressed 2-adrenoceptor, to 338 
study functional outcomes of two conformations (tail and core) of GPCR-arrestin complexes. 339 
By expressing a mutant arrestin that only forms a tail conformation alongside either a β2-340 
adrenoceptor or a chimeric β2-adrenoceptor/V2 vasopressin receptor in these triple knock-out 341 
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cells, Cahill 3rd et al. [49] showed that this conformation suffices to recruit an arrestin 342 
effector molecule and to internalise ligand-activated receptors, whilst desensitisation of G 343 
protein signalling was not induced. 344 
Concluding Remarks  345 
Applications of genome-editing approaches, particularly in well studied and widely 346 
used model cell systems, have already provided important new insights into the relative roles 347 
of G protein- and non G protein-mediated signalling from variety of cell surface GPCRs. As 348 
with earlier methods able to ‘knock-down’ expression of gene products, the earliest described 349 
CRISPR/Cas9-based methods were recognised to have potential ‘off-target’ effects (Text 350 
Box 4) [50]. However, as methods have improved and developed this is now less of a concern 351 
(Text Box 4).  As with many other revolutions in molecular biology, pharmacologists need to 352 
rapidly adopt and appreciate the power and potential of genome-editing. Ways in which it 353 
will influence understanding of the modes of action of drugs and tool compounds and of the 354 
mechanisms of signal transduction are already manifest (Outstanding questions), and its 355 
applications and potential seem limited only by the imagination of experimental scientists. 356 
 357 
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Text Boxes 518 
Abbreviations used in Text Boxes  519 
DSB, double-strand break  520 
FACS, fluorescence activated cell sorting  521 
NHEJ, non-homologous end joining  522 
PAM, protospacer-associated motif  523 
RE, restriction enzyme  524 
sgRNA, single guide RNA  525 
 526 
Text Box 1  527 
A CRISPR/Cas9 system utilises a RNA-guided endonuclease derived from bacteria or 528 
archaea [50]. The RNA loaded in a Cas9 endonuclease (CRISPR RNA, crRNA) guides the 529 
Cas9 complex to complementary sequence of target DNA and allow the Cas9 endonuclease 530 
to induce a double-strand break (DSB) in this DNA. Cleavage of target DNA by Cas9-crRNA 531 
requires a short nucleotide sequence called a protospacer-associated motif (PAM), flanking 532 
the 3´ site of the crRNA complementary sequence. Streptococcus pyogenes Cas9, the most 533 
routinely used Cas9, recognises 5’-NGG-3’ PAM. When applied to mammalian cells, 534 
expression of two components is sufficient to induce a DSB: Cas9 that contains a nuclear 535 
localisation signal and a single guide RNA (sgRNA) that mimics function of crRNA. After 536 
induction of a DSB, host cells repair the cleavage and random insertion/deletion is introduced 537 
by a non-homologous end joining (NHEJ) pathway. This results in disruption (insertion, 538 
deletion or truncation) of an encoded protein. 539 
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Effective targeting of a gene locus depends on functional domains/motifs of its 540 
encoded protein. For G protein  subunits amino acid residues critical for effective 541 
interactions with GPCRs are located within the extreme C-terminal region [51]. Thus, a 542 
frame-shift mutation at any position in the protein open-reading frame is expected to nullify 543 
G protein function due to a lack of GPCR-induced activation. A frame-shift mutation usually 544 
leads to the emergence of a premature stop codon. When this type of stop codon appears 5’ 545 
upstream of the last exon the mRNA undergoes nonsense-mediated mRNA decay [52]. This 546 
results in smaller amounts of a truncated protein than of the full length native protein. As a 547 
NHEJ repair can introduce a random, in-frame mutation, it is preferable to design a sgRNA 548 
sequence to target a site encoding a residue critical for protein function. For example, 549 
nucleotide-interacting residues, and flexible loops (Finger loop, Middle loop and Lariat loop) 550 
are critical for function of G protein  subunits (GDP/GTP binding) and arrestins (GPCR 551 
binding) [53], respectively. For GPCRs, highly conserved sequence amino acid motifs (e.g. 552 
Asp-Arg-Tyr (DRY) at the cytoplasmic face of transmembrane domain 3 and (Asn-Pro-Xaa-553 
Xaa-Tyr (NPxxY) in transmembrane domain 7) are key targets. An in-frame mutation near 554 
these residues is expected to ablate protein function. Another potentially effective target site 555 
is a splicing acceptor/donor sequence. Since RNA splicing occurs at conserved sequences 556 
(GG-GU and AG-G (hyphen denotes a cleavage site) for a donor and an acceptor, 557 
respectively), disruption of these nucleotides can result in skipping of proper RNA splicing 558 
and loss of mature protein. 559 
 560 
  561 
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Text Box 2  562 
Although widely used for pharmacological studies and able to be transfected with 563 
high efficiency HEK293 cells are known to be polyploid (i.e. cells contain more than two full 564 
copies of the genome) [54]. Although the precise karyotype varies among sub-clones and 565 
probably between individual laboratories HEK293 cells are roughly triploid. From a genome-566 
editing standpoint polyploidy is challenging because all of the alleles encoding the gene of 567 
interest must be modified and the probability of obtaining an ‘all-allele edited’ clone 568 
(preferably all with frame-shift mutations) is exponentially less likely as numbers of target 569 
alleles or target genes increase. Thus, it is essential to design and validate effective and easy-570 
to-genotype sgRNA constructs. Various online tools to support sgRNA design (minimising 571 
scores for potential ‘off-target’ effects (Text Box 4) and increasing on-target scores) are 572 
available (for example, CRISPR Design, http://crispr.mit.edu; CRISPRdirect, 573 
https://crispr.dbcls.jp; CRISPRko, https://portals.broadinstitute.org/gpp/public/analysis-574 
tools/sgrna-design). When multiple-gene targeting is performed, we design three sgRNAs per 575 
gene and test mutagenesis activity in a pool of sgRNA/Cas9-expressing cells so that we can 576 
select and mix the most highly active sgRNAs to be transfected. For genotyping, we prefer a 577 
restriction enzyme (RE)-based method (Figure I), in which the RE recognises an unmodified 578 
sequence at a DSB but fails to digest it once a random mutation is introduced at the RE site. 579 
Compared with other genotyping methods (e.g. mismatched hybrid-recognising nuclease and 580 
heteroduplex mobility analysis), the RE-based method is sensitive for discriminating all-581 
allele mutations from heterozygous mutation, although numbers of candidates sgRNA 582 
sequences may be quite limited. Since HEK293 cells carry on average three alleles per gene 583 
direct sequencing (e.g. Sanger sequencing of a PCR-amplified fragment) is often not feasible 584 
because electrographs with more than two waves (distinct mutations) are impractical to 585 
deconvolute. We prioritise candidate clones by utilising capillary electrophoresis which has 586 
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resolution of a few base pairs and can discriminate clones with a single PCR band from those 587 
with multiple bands. Clones with a single band are more likely to carry an identical mutation 588 
in two or more alleles, in which case sequence can be determined by a direct sequencing 589 
method. It is important to validate loss of the targeted gene products in isolated clones as 590 
sequencing alone sometimes fails to detect a hypomorphic (functionally residual) allele. Such 591 
validation assays include Western blot analysis (protein expression) and functional GPCR 592 
assays to monitor downstream signalling. Notably, it is essential to perform re-expression 593 
experiments (recovery of an observed phenotype with re-introduction of the targeted gene) to 594 
avoid artefacts associated with ‘off-target’ effects of Cas9 genome-editing (Text Box 4). 595 
From our experience a highly active sgRNA construct is able to generate an all-allele, frame-596 
shift mutant with probability of 10-20% in HEK293 cells. When two genes are 597 
simultaneously targeted, this probability is reduced to approximately 1-4%. 598 
  599 
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Text Box 3 600 
Until recent times, beyond gene knock-out strategies in both mice and less complex 601 
model organisms, the only practical way to inactivate members of a G protein  subunit 602 
subfamily was via the ADP-ribosyltransferase activity of pertussis toxin [38](Figure II). Of 603 
the Gi subgroup the  subunits of all bar Gz have a Cys residue located 4 amino acids from 604 
the C-terminus and pertussis toxin catalyses addition of ADP-ribose to this amino acid [38].  605 
This prevents effective interactions with agonist-occupied GPCRs. Initial introduction of the 606 
cell permeable Gq/G11/G14 inhibitor YM-254890 [21] (Figure II) allowed selective targeting 607 
of this class of G proteins.  However, YM-254890 is not an effective inhibitor of the GPCR 608 
promiscuous G15/G16 G proteins from rodent (G15)/human (G16) (but these display very 609 
limited tissue distribution). Subsequent discovery of the related molecule FR900359 [18], 610 
with similar characteristics and G protein selectivity as YM-254890 (Figure II), has 611 
expanded the tools available. Further G protein subtype selective inhibitors would be 612 
exceptionally useful additions but genome-editing offers an alternative and potentially more 613 
broad-ranging approach with the potential to allow elimination of multiple G protein  614 
subunits and across subfamilies (see Main text for details).  615 
  616 
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Text Box 4 617 
Although Cas9-induced genome editing is efficacious it is known that Cas9 causes 618 
mutations at ‘off-target’ sites that have sequence similarity with a sgRNA. As such it is 619 
important that experimental artefacts associated with potential ‘off-target’ mutations should 620 
be considered. To validate that an observed cellular response in genome-edited cells is 621 
mediated by the targeted gene product and not by an ‘off-target’ effect, it is essential to 622 
perform re-expression analysis (see Main text for examples). For example, if a GPCR-623 
induced cellular response is lacking in cells from which a G protein subunit has been 624 
targeted, recovery of function or phenotype should occur following re-introduction of a 625 
plasmid able express the targeted polypeptide. Although in many cases transient expression 626 
of such a plasmid is sufficient to rescue a phenotype, it should also be considered whether 627 
appropriate and sufficient expression levels are achieved by so doing so.   628 
Unlike genetically modified organisms (e.g. knockout mice), in which ‘off-target’ 629 
mutations can be removed by back-crossing with a wild-type animal, mutations in cell lines 630 
are not easily overcome. Furthermore, it is impractical to identify effectively all potential 631 
‘off-target’ mutations in genome-edited cell lines unless accurate genome sequence is 632 
performed. Thus, it is important to avoid the generation of such ‘off-target’ mutations. 633 
Several high-fidelity Cas9 variants have been generated recently that are useful for reducing 634 
off-site genome modifications. For example, Cas9 nickase [55] induces a nick at the targeted 635 
site and DSB occurs only when two Cas9 nickases target a proximal site in complementary 636 
and non-complementary DNA sequences. This requires simultaneous binding of two Cas9-637 
sgRNA complexes and thus reduces substantially the probability of non-specific DSB. Other 638 
examples are Cas9 variants [56, 57, 58] designed using rational structural analysis and these 639 
have reduced non-specific DNA contacts while maintaining on-target activity. With ongoing 640 
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efforts next-generation, high-fidelity Cas9 variants will pave a way to generate gene-641 
knockout cells free from off-target-effects. 642 
  643 
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Figure Legends (Main Text) 644 
Figure 1 645 
GPCR effectors and their expression by HEK293 cells  646 
As well as a broad array of GPCRs [5] parental HEK293 cells express at detectable 647 
levels the  subunits of members of each of the four broad subgroups [38] of heterotrimeric 648 
G proteins.  Gα subunits (and other GPCR regulators) in dark colours are not expressed at 649 
detectable levels. In addition HEK293 cells also express both arrestin-2 and arrestin-3. 650 
Although outwith the topics covered in this review HEK293 cells are also known to express 651 
some members of the families of G protein-coupled receptor kinases (GRK)(GRKs 2, 3, 5 652 
and 6) [59] and Regulators of G protein Signaling (RGS) proteins that modify and regulate G 653 
protein-mediated signalling cascades. Although Gαz is not a substrate for pertussis toxin-654 
catalysed ADP-ribosylation, all the other Gi-family Gα subunits are.  Because this 655 
modification prevents GPCR-mediated activation of these G proteins and, therefore, can be 656 
used to chemically eliminate signalling via this group, these have not been reported, to date, 657 
to have been eliminated in HEK293 cells by genome-editing. By contrast, members of each 658 
of the other three subfamilies have been eliminated, sometimes in combinations, from 659 
HEK293 cells by CRISPR/Cas9-mediated genome-editing. Alongside HEK293 cells from 660 
which both arrestin-2 and arrestin-3 have been eliminated, these cell lines have provided a 661 
novel toolbox to explore roles of these polypeptides (see Main text for details).   662 
 663 
Figure 2 664 
Genome-editing of HEK293 cells illustrates the contribution of Gq and G12 G 665 
proteins family subunits to GPCR-mediated shedding of TGF  666 
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Shedding of cell surface expressed alkaline phosphate-linked TGF(yellow 667 
stick)from HEK293 cells in a ADAM-17 (purple)-dependent manner was introduced as a 668 
widely applicable means to identify agonists able to activate a very broad range of GPCRs 669 
[39] in wild type HEK293 cells. Initial studies suggested that this endpoint required 670 
activation of some combination of Gq and G12 family G protein subunits (A). Genome 671 
editing to eliminate expression of either both G12 and G13 (B) or Gq and G11 (C) was 672 
insufficient to eliminate this endpoint when activating co-expressed Free Fatty Acid Receptor 673 
2. However, elimination of all four of these G protein  subunits abrogated shedding of 674 
TGF(D). Receptor function was restored by re-introduction of any of these four individual 675 
G proteins (E) or by re-introduction of various chimeric G proteins (F). The cartoon is 676 
derived from data presented in [34].  677 
 678 
Figure I (within Text Box 2) 679 
Generation of HEK293 cells lacking expression of G protein  subunits using 680 
CRISPR/Cas9 genome editing 681 
The steps described in Text Box 2 to perform and validate successful genome-editing 682 
of HEK293 cells to eliminate expression of the G12 G protein subunit are illustrated. As 683 
highlighted in the text, HEK293 cells are polyploid and therefore in the illustration three 684 
alelles are indicated, with successful targeting of all three being required to eliminate 685 
expression. A. Illustrates steps to target a specific gene whilst B. and C. illustrate steps 686 
required to verify isolation of a successfully genome-edited clone. 687 
 688 
Figure II (within Text Box 3) 689 
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Currently available G protein inhibitors  690 
The identity and target selectivity of currently available inhibitors of various G 691 
proteins classes is illustrated. This highlights the dearth of such inhibitors and the potential of 692 
genome-editing to overcome this lack of effective tool compounds.  693 
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Glossary 694 
Agonist: a chemical species which binds to a receptor and activates it, eliciting a biological 695 
response.  696 
 697 
Antagonist: a chemical species which binds to a receptor preventing activation by an agonist.  698 
 699 
AZ1729: N-[3-(2-carbamimidamido-4-methyl-1,3-thiazol-5-yl)phenyl]-4-fluorobenzamide. 700 
An allosteric agonist of the Free Fatty Acid 2 receptor. This ligand displays capacity to 701 
produce signals via this GPCR that proceed via activation of Gi-family G proteins but not via 702 
Gq/G11 or G12/G13 G proteins [34, 41]. 703 
 704 
Chimeric G protein  subunit: a G protein  subunit containing elements of sequence from 705 
a minimum of two different G proteins. In most examples the C-terminal 5-10 amino acids of 706 
one G protein are exchanged for the corresponding sequence from a second G protein [38]. 707 
 708 
CRISPR/Cas9: Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-709 
associated genes. A method for genome-editing (see Text Box 1 for details). 710 
 711 
FR900359: [(1R)-1-[(3S,6S,9S,12S,18R,21S,22R)-21-acetamido-18-benzyl-3-[(1R)-1-712 
methoxyethyl]-4,9,10,12,16-pentamethyl-15-methylidene-2,5,8,11,14,17,20-heptaoxo-22-713 
propan-2-yl-1,19-dioxa-4,7,10,13,16-pentazacyclodocos-6-yl]-2-methylpropyl] (2S,3R)-3-714 
hydroxy-4-methyl-2-(propanoylamino)pentanoate. A synthetic inhibitor of Gq, G11 and G14 G 715 
proteins [16, 17, 18]. 716 
 717 
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G Protein-Coupled Receptor (GPCR): integral membrane protein able to transmit signals 718 
across the cell membrane in response to an external stimulus, to activate (usually) 719 
heterotrimeric guanine nucleotide binding proteins (G proteins). GPCRs are characterised by 720 
a conserved structure comprising 7 helical membrane spanning domains, an extracellular N-721 
terminus, 3 external loops, 3 internal loops and an internal C-terminal domain. Sub-divided 722 
into classes based upon structural relatedness. 723 
 724 
Knock-down: Introduction into cells of an oligonucleotide sequence that is complementary 725 
to specific mRNA sequences.  This results in destruction of the corresponding mRNA. By 726 
preventing new protein synthesis from the mRNA this, over time, results in reduction in level 727 
of the corresponding protein. 728 
 729 
Knock-out: a model organism (frequently mouse) in which one or more specific genes have 730 
been modified such that expression of corresponding mRNA/protein is lacking. 731 
 732 
Null background: cells, frequently model systems used for ligand screening, that are known 733 
not to express endogenously the molecular target of interest. 734 
 735 
Orphan (GPCR): A receptor for which endogenous activating ligands remain unidentified or 736 
where suggested ligands are not fully accepted by the research community. 737 
 738 
 35 
 
Shedding assay: Release of an alkaline phosphatase-linked form of transforming growth 739 
factor  (TGF) from the surface of transfected cells in a ligand (usually GPCR agonist)-740 
dependent manner [39].  741 
 742 
TALEN: Transcription activator-like effector nucleases. An alternate approach to genome-743 
editing based on restriction enzymes engineered to cut specific sequences of DNA. 744 
 745 
YM-254890: A cyclic peptide isolated initially from the soil bacterium Chromobacterium sp. 746 
QS3666 strain that selectively inhibits Gq, G11 and G14 G proteins [21]. 747 
 748 
 749 
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sgRNA target construction
(~1 weeks)
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Hind III recognition site
Hind III site Cas9-induced mutations(colors denote different mutations)
5’ ...CGAGATAAGCT|TGG... -3’
3’ ...GCTCTATTCGA|ACC... -5’
Designing sgRNA seqeunces
(typically, three constructs per gene)
Ordering synthelized oligonucleotides
Inserting an oligonucletide duplex (sgRNA)
into a Cas9-GFP-encoded plasmid
Sequencing the inserted sgRNA
Single clone isolation and
genotype screening
(~3 weeks)
Transfecting a sgRNA/Cas9 plasmid
FACS-isolating GFP-positive cells
(sgRNA/Cas9-transfected cells)
Seeding FACS-isolated cells in a 96-
well plate in a limiting dilution (1 cell per
well for 10 plates and 2 cells per well
for 10 plates)
Adding medium at least every 1 week
Checking colony growth
Passaging and genotyping colonies
Splitting harvested cells into a 6-well
plate and a microtube
Validation of gene-knockout
clones and a re-expression
experiment (~3 weeks)
Passaging and splitting cells into
a 10-cm dish (for stock) and desired
dishes (assays)
Harvesting and freezing cells
Western blot (protein expression)
Downstream signaling (protein function)
TA cloning (target allele sequence)
Passaging cells into assay dishes
Transfecting an expression plasmid
encoding an ORF of the targeted gene
Testing phenotypic “rescue” upon
re-expression of the targeted gene
10-cm dish
assay dishes
Harvest transfected cells
Isolate GFP-positive cells using
a FACS
Transfect a Cas9- and sgRNA-
encoding plasmid
Seed HEK293 cells
Isolate single-cell-derived
colonies by a limiting dilution
method
Check grown clonies
Harvest colonies and split cell
suspension into a 6-well plate
(for culture) and a microtube
(for genotyping)
Passage cells into a 10-cm dish
Seed cells for functional assays
and/or harvest cells for protein
expression
1 day
3 day
~2 weeks
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G protein inhibitors Targets Disadvantages/concerns
Pertussis toxin Gi family Ga subunits
(except for Gz)
Long-term treatment is required (typically overnight)
YM-254890, FR900359
and analogues
Gq family inhibitors
(except for G15/16)
Compound may be rapidly degraded
General issues with G protein inhibitors
• Inhibitors affect only subsets of G protein subfamily members
• Washout and functional recovery/rescue experiments are difficult to perform
Outstanding Questions  
Can cell lines be developed that lack expression of all G protein  subunits? 
As HEK293 cells express detectable amounts of 13 distinct G protein  
subunits (Figure 1) the only practical means to approach total elimination is in 
a step-wise fashion. Given the key roles G proteins play in transmembrane 
signalling, elimination of further family members may result in very poor 
growth characteristics of such cells.  
  Elimination of expression of G protein  and/or  subunits? 
Given the complexity of the potential number of distinct G  pairings and 
that older studies using antisense-based ‘knock-down’ suggested distinct 
functions for many such pairs, the generation of such lines and their analysis 
would be a substantial task.  
 
Elimination of expression of G protein-coupled receptor kinases? 
The contribution of members of the G protein-coupled receptor-(GRK) 
(Figure 1) and second-messenger-regulated kinases to ligand-induced 
phosphorylation of GPCRs has been controversial and challenging to assess, 
due in part to a lack of useful and selective inhibitors of GRK subtypes. 
Genome-editing would appear to offer a means to (re)-assess these issues. 
 
Use of genome-editing to introduce point mutations/polymorphisms into GPCRs and 
signalling pathway components?  
Although transfection of cDNAs mutated to encode point-mutants and non-
synonomous single nucleotide polymorphisms is a standard approach, this 
frequently results in high level over-expression of the variant protein. 
Introduction of such variants into cells that endogenously express a receptor or 
signalling protein of interest via genome-editing may ensure more native 
expression levels in the absence of the wild type protein sequence.  
